Finnegan's Take

Archives for pharmaceuticals

Doctors from across Europe are gathering in Athens on Saturday for an emergency meeting amid fears that the Greek health system is going into meltdown. The hastily-arranged medical summit, called by the Medical Association of Athens, is due to discuss plans for a new European Medical Network through which doctors could support the ailing health… » read more

Posted by Gary Finnegan

Three years after it was proposed the EU Information to Patients Directive is in limbo European health ministers have poured cold water on a long-standing EU proposal to allow pharmaceutical companies to provide information on medicines directly to patients. Ministers say the Information to Patients Directive could increase red tape for government agencies and companies… » read more

Posted by Gary Finnegan

Chronic drug shortages in Greece have left thousands of patients without medicines and paralysed the drug supply chain. The impact of the ongoing financial crisis in Europe is having a deep impact on patients – and that’s before the possible return of the Drachma which could at least double the relative cost of imported medicines.… » read more

Posted by Gary Finnegan

Fears that Greece could default on its debt tops the EU agenda because it puts the balance sheets of a dozen German and French banks in peril. But Greece has already defaulted on its debts to companies. What is default? EU leaders have been trying to find a way around the fact that Greece cannot… » read more

Posted by Gary Finnegan

The EU’s clinical trials directive has been a catastrophe but Brussels is keen to make amends “Arguably the most criticised piece of legislation” the EU has ever produced on medicines. That’s how the European Commission describes its own law on clinical trials, drafted a decade ago in an effort to streamline medical research in Europe.… » read more

Posted by Gary Finnegan

Shock! Horror! NGOs have gotten their way despite fierce resistance from the pharma industry Pharmaceutical policy will move to the European Commission’s health and consumer wing, DG Sanco, as part of a shake-up of responsibilities by President Barroso. This means control of medicines, which rested with DG Entrprise & Industry, is now under the wing… » read more

Posted by Gary Finnegan

Sitting listening to the EU’s enterprise commissioner holding forth at the European Parliament’s environmental committee on the subject of regulating medicines, I was prompted to wonder how the status of health policy could be so low. Swine flu, counterfeit drugs, and our ageing population are supposed to be priorities but health is an afterthought. The… » read more

Posted by Gary Finnegan